oxytocin

Trade name: syntocinon

Peptideapproved

Approved

Apr 17, 1980

More than a century ago, Sir Henry Dale demonstrated that a component of the pituitary causes contractions of the mammalian uterus, hence his coining the term “oxytocic,” derived from the Greek for “quick birth,” for its activity. The discovery that a component of the pituitary causes milk secretion followed within a few years. By 1930, oxytocin was separated from vasopressin into pitocin and pitressin, respectively, at Parke Davis and made available for research. That a single peptide was responsible for these uterine and mammary actions was definitively confirmed upon the sequencing and synthesis of the peptide, 9 amino acids in length. Vincent du Vigneaud was awarded a Nobel Prize for this work. Oxytocin is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable for reasons of fetal or maternal concern, in order to achieve vaginal delivery. Oxytocin is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage. Uterine motility depends on the formation of the contractile protein actomyosin under the influence of the Ca2+- dependent phosphorylating enzyme myosin light-chain kinase. Oxytocin promotes contractions by increasing the intracellular Ca2+. Oxytocin has specific receptors in the myometrium and the receptor concentration increases greatly during pregnancy, reaching a maximum in early labor at term. The Oxytocin receptor is a typical class I G protein-coupled receptor that is primarily coupled via G(q) proteins to phospholipase C-beta. The high-affinity receptor state requires both Mg(2+) and cholesterol, which probably function as allosteric modulators. The agonist-binding region of the receptor has been characterized by mutagenesis and molecular modeling and is different from the antagonist binding site. The function and physiological regulation of the Oxytocin system is strongly steroid dependent. — NCATS

Clinical trial activity

623 trials · 341 clinical orgs · 13 marketing orgs

Phase 1
116
Phase 2
184
Phase 3
57
Phase 4
86

Earliest trial started Jan 1, 2002 (NCT00405158)

Timeline

1980s

  1. Apr 17, 1980

    Novartis — Earliest FDA Approval

  2. Apr 17, 1980

    Novartis — NDA Secondary Org

  3. Apr 17, 1980

    Novartis — NDA Organization

  4. Apr 29, 1980

    West-Ward Pharmaceutical — NDA Secondary Org

  5. Apr 29, 1980

    Hikma — NDA Secondary Org

  6. Jul 9, 1980

    Fresenius — NDA Secondary Org

  7. Nov 19, 1980

    Endo Pharmaceuticals — Marketing Organization

  8. Nov 19, 1980

    Par Pharmaceuticals — NDA Secondary Org

  9. Nov 19, 1980

    PH HEALTH — Marketing Organization

  10. Mar 29, 1985

    Abbott — NDA Secondary Org

2000s

  1. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2007

    Earliest Phase 3 Sponsor(trial)

  4. Jan 24, 2008

    Teva — Marketing Organization

  5. Jan 24, 2008

    Dr. Reddy's Laboratories — Marketing Organization

2010s

  1. Feb 13, 2013

    Hikma — Marketing Organization

  2. Jul 13, 2018

    Sagent Pharmaceuticals, Inc. — Marketing Organization

  3. Jul 13, 2018

    Nichi-Iko Pharmaceutical Co., Ltd. — Marketing Organization

Indications

Studied for

Mechanism of action

Approval history

  • approvedApr 17, 1980

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Mol. weight
1007.21 g/mol
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral, Topical
Availability
Prescription Only
Multi-specific
No

Oral

No

Parenteral

Yes

Topical

Yes

Black box warning

Sources

Also known as

  • orasthin
  • orasthin
  • orasthin
  • oxymetrin
  • oxystin
  • oxytocin
  • oxytocin
  • oxytocin
  • oxytocin
  • oxytocin
  • oxytocin
  • oxytocin
  • oxytocin
  • oxytocin
  • oxytocin
  • oxytocin
  • oxytoine
  • partocon
  • perlacton
  • pitocin
  • pitocin
  • pitocin
  • synthetic oxytocin
  • syntocinon
  • syntocinon
  • syntocinon
  • syntometrine
  • syntometrine
  • syntometrine
  • vagitocin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07053774Phase 2Nov 5, 2025Atrium Medical Center, Wake Forest University
NCT06968481Phase 2Oct 1, 2025Insud Pharma
NCT07188207N/AOct 1, 2025Assiut University
NCT07140237Early Phase 1 (Phase 1)Sep 30, 2025University of Electronic Science and Technology of China
NCT06930391N/ASep 15, 2025Icahn School of Medicine at Mount Sinai
NCT07162584N/ASep 13, 2025University of Electronic Science and Technology of China
NCT07265180N/ASep 8, 2025Humboldt University
NCT07119398Phase 4Jul 14, 2025Eastern Virginia Medical School
NCT07006896N/AJul 10, 2025University of Pennsylvania
NCT06990217Phase 4Jun 30, 2025Emek Medical Center
NCT07093060Early Phase 1 (Phase 1)Jun 9, 2025University of Electronic Science and Technology of China
NCT06945926Phase 2Jun 1, 2025Zhejiang University
NCT06881459N/AMar 25, 2025University of Copenhagen
NCT06808516Phase 2Feb 28, 2025University of Basel
NCT06676774Phase 2Jan 10, 2025University of Basel
NCT06651476Phase 2Dec 31, 2024National Institute of Neurological Disorders and Stroke (NINDS), Wake Forest University
NCT06364228Phase 2Nov 30, 2024University of Nebraska
NCT06580782Phase 4Nov 18, 2024Cornell University
NCT06550089Phase 2Oct 31, 2024Medical College of Wisconsin, University of Chicago
NCT06333340N/AOct 31, 2024Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, Canada
Showing 20 of 623 trials
Page 1 / 32

Organizations

Research & Development (341)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of Electronic Science and Technology of ChinaAcademic/Hospital464622014
Icahn School of Medicine at Mount SinaiAcademic/Hospital333042005
Harvard UniversityAcademic/Hospital232152009
Cairo UniversityAcademic/Hospital222152011
Wake Forest UniversityAcademic/Hospital191932014
Department of Veteran AffairsGovernment15732010
University of California, San FranciscoAcademic/Hospital151442010
Ain Shams UniversityAcademic/Hospital141352012
Tel Aviv UniversityAcademic/Hospital141242008
University of BonnAcademic/Hospital141412011
Assiut UniversityAcademic/Hospital131242012
Medical University of South CarolinaAcademic/Hospital13632011
University of North Carolina at Chapel HillAcademic/Hospital131342009
Mount Sinai Hospital, CanadaAcademic/Hospital11012018
National Institute of Mental Health (NIMH)Government10252008
University of FloridaAcademic/Hospital10842013
Technion UniversityAcademic/Hospital9732011
University of California, San DiegoAcademic/Hospital9642008
University of ToulouseAcademic/Hospital9932009
Yale UniversityAcademic/Hospital9742007
341 organizations
Page 1 / 18

Marketing (18)

OrganizationOrg typeRelationshipDate
AbbottFor profitNDA2Mar 29, 1985
AsklepionFor profitNDA2
Dr. Reddy's LaboratoriesFor profitMKTGJan 24, 2008
Endo PharmaceuticalsFor profitMKTGNov 19, 1980
FreseniusFor profitNDA2Jul 9, 1980
HikmaFor profitMKTGFeb 13, 2013
HikmaFor profitSYNApr 29, 1980
HikmaFor profitSYNApr 29, 1980
HikmaFor profitNDA2Apr 29, 1980
Nichi-Iko Pharmaceutical Co., Ltd.For profitMKTGJul 13, 2018
NovartisFor profitNDA2Apr 17, 1980
NovartisFor profitNDAApr 17, 1980
PH HEALTHFor profitMKTGNov 19, 1980
Par PharmaceuticalsFor profitNDA2Nov 19, 1980
Sagent Pharmaceuticals, Inc.For profitMKTGJul 13, 2018
Sagent Pharmaceuticals, Inc.For profitSYNJul 13, 2018
TevaFor profitMKTGJan 24, 2008
West-Ward PharmaceuticalFor profitNDA2Apr 29, 1980